Aroa Biosurgery Ltd · ASX:ARX
Aroa Biosurgery — Corporate Update (January 2023)
15 slides from Aroa Biosurgery's corporate update, Jan 31, 2023
Slide 1: Aroa Biosurgery (ARX) Quarterly Update January 2023
For personal use only AROA BIOSURGERY (ARX) QUARTERLY UPDATE JANUARY 2023 Unlocking regenerative healing for everybody
Slide 2: Important Notice and Disclaimer
|2 Important Notice and Disclaimer This presentation (Presentation) is dated 31 January 2023 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). For personal use only Information in this Presentation The information in this Presen
Slide 3: Quarterly cash flow
|3 Quarterly cash flow For personal use only Cash receipts from customers of NZ$17.1 million during the quarter. Net cash inflow from operations of NZ$0.2 million for the quarter. Net cash outflow from investing activities was NZ$2.0 million for the quarter, reflecting AROA’s investment into plant &
Slide 4: Guidance
|4 Guidance1 For personal use only Forecast Product Revenue Forecast Product Gross Normalised EBITDA2 NZ$60-62m Margin ~breakeven Total revenue of NZ$62-64m 84% Cash Balance ~NZ$50m 1. Given the dynamic and evolving impact of COVID-19, all forward looking statements in relation to FY23 performance a
Slide 5: Myriad
|5 Myriad™ Myriad is the major growth driver: in-line with plan. For personal use only Myriad Morcells™: conformable graft with notable persistence. Ongoing field salesforce expansion: currently 40 (+5), targeting ~41 by end of FY23. Salesforce productivity: 123 active Myriad accounts,1 4 reps with
Slide 6: Symphony
|6 Symphony™ New high value product: for treating DFUs and For personal use only VLUs in outpatient wound centers and physicians’ offices. Similar to Myriad and augmented with Hyaluronic Acid: designed to support enhanced cell migration and improve moisture management. Full Launch Apr ’23: Preparing
Slide 7: OviTex & OviTex PRS
|7 OviTex™ & OviTex PRS For personal use only OviTex, OviTex LPR & OviTex PRS continue to gain momentum: TELA Bio™ 60 field reps, sales guidance of US$42-45m in CY22 (up from US$29.5m in CY21.1) Bravo I (ventral hernia): 92 enrolled patients, 2.6% recurrence rate in ventral hernias at 24- months.2 R
Slide 8: Endoform
|8 Endoform New Study: Endoform Natural - High Flow ensures that therapeutic For personal use only NPWT pressures are delivered to the wound bed providing potential for better healing outcomes vs. alternate collagen-based matrices.1 Modest growth: serviced by remote inside sales team. Clinical evide
Slide 9: Enivo
|9 Enivo™ For personal use only US FDA 510k submission: Nov ’22. Set-up for pilot clinical study: 10 patients in US Total Mastectomy H1 CY23. Recruiting begins March Addressable ‘23 . Market >$1B (AROA management Pre-clinical model demonstrates efficacy estimate) potential: Peer-reviewed publication
Slide 10: Other Operational highlights
| 10 Other Operational highlights For personal use only Manufacturing: Upgrading and expanding tissue processing facility. Ex-US: Myriad Matrix™ approval in Brazil, Canadian GPO Contract for Endoform with HealthPRO (1,300 members). Patent portfolio update: 19 registered patents, 35 pending and a fur
Slide 11: FY23 Catalysts & Milestones
| 11 FY23 Catalysts & Milestones For personal use only AROA Sales TELA AROABioSales Sales Symphony Product Post-COVID Launch Momentum Momentum Momentum COVID-19 expected to have a reduced impact for remainder of FY23 Clinical outcomes & cost savings Well suited to evolving Fully dedicated Fully dedi
Slide 12: Contacts
CONTACTS For personal use only Simon Hinsley Matt Wright Sarah Tora Investor Relations Media Corporate Communications Manager m +61 401 809 653 m +61 451 896 420 m +64 21 531 043 shinsley@aroabio.com matt@nwrcommunications.com.au sarah.tora@aroabio.com Visit our website www.aroabio.com and find us o
Slide 13: AROA at a Glance
| 13 AROA at a Glance Well established high-growth soft tissue regeneration company For personal use only Four product AROA ECM™ platform families for new products, line extensions >US$2.5b2 TAM predominantly sold to US & enables AROA’s tissue apposition platform for existing products hospitals US D
Slide 14: Substantial Growth Opportunities >$2.5B TAM
Substantial Growth Opportunities > $2.5B1 TAM For personal use only Complex Wounds Soft Tissue Reconstruction Total Addressable Market Total Addressable Market > $1.4B2 USD > $1.3B3 USD e.g. Diabetic Foot Ulcers, e.g. Trauma, tumour removal, e.g. Hernia repair, abdominal Venous Ulcers, Pressure Ulce
Slide 15: AROA ECM – Structure & Biology for Regenerative Healing
| 15 AROA ECM – Structure & Biology for Regenerative Healing Unique Extracellular Matrix (ECM) derived from ovine forestomach with proven tissue regeneration properties across multiple products1-6 For personal use only 1. Irvine, S. M., et al. (2011). "Quantification of in vitro and in vivo angiogen